Lillie James Woodruff sold $277K of MPLT
Lillie James Woodruff (Chief Scientific Officer) sold 22,082 shares of MapLight Therapeutics, Inc. (MPLT) at $12.54 ($0.28M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale by the Chief Scientific Officer, executed under a pre-arranged Rule 10b5-1 plan, which generally reduces interpretive weight versus discretionary selling.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of new fundamentals make this more of a monitoring item than a catalyst.
What to watch
The article does not state whether the insider’s remaining holdings are subject to other plans, nor does it provide context on prior sale cadence.
Background
The article is an SEC Form 4 insider transaction for MapLight Therapeutics, Inc. (MPLT).
Ticker impact
MapLight Therapeutics insider Lillie James Woodruff sold 22,082 shares in an open-market transaction under a 10b5-1 plan.
Likely minimal near-term impact; any effect would be sentiment-only and typically fades.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no new company-specific fundamentals beyond the sale details.
Market effects
No direct sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can be purely mechanical and may not reflect bearish expectations.
Key entities
- issuerMapLight Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderLillie James Woodruff
Chief Scientific Officer who sold 22,082 shares.